Interview with Peter van Tilburg, General Director / President, Cambridge Major…
It has now been 12 years since you co-founded ChemShop. One of the busiest, but probably most exciting moments in that period must have been the merger with CML in…
Address: Cambridge Major Laboratories Europe, B.V., Peelterbaan 2, 6002 NK Weert, Industrial area “De Kempen”, the Netherlands
Tel: ++31 (0)495 549 072
Web: http://www.c-mlabs.com/faceu.html
Cambridge Major Laboratories provides advanced chemistry services to the worlds leading pharmaceutical and biotechnology companies. We boast an impeccable reputation for delivering some of the most challenging projects and meeting the tightest timelines. And Cambridge Major’s reach is truly global in nature, operating four facilities in the US and Europe, serving hundreds of companies across the world.
Our philosophy revolves around strong R&D. With almost 50% of our scientists holding a Ph.D., Cambridge Major is well positioned to deliver on the most challenging and complex chemistry projects. Strong R&D to support early scale up during pre-clinical development will ensure that your molecule will transition into first-in-human studies as smoothly as possible. And we have the resources to provide all of your clinical and commercial API needs.
So when you are looking for a trusted partner to help take your molecule from concept to clinic and beyond, look to Cambridge Major. WE DELIVER.
The Weert facility (formerly ChemShop BV) is a 12,500 square meter site specializing in medicinal chemistry, process development, scale-up, clinical supplies, and low volume commercial supply of API’s. The facility houses fully isolated pilot suites with reactors of up to 1000 liter, and is fully GMP and ISO14001 certified. The facility has a wide range of capabilities including plant scale cryogenics (-100C) and high temperature (300C), high pressure reactions and high vacuum distillations.
It has now been 12 years since you co-founded ChemShop. One of the busiest, but probably most exciting moments in that period must have been the merger with CML in…
Speaking to PharmaBoardroom in the context of our upcoming InFocus special report on HIV, Access to Medicine Foundation CEO Jayasree Iyer looks back on pharma’s successes and failures in access…
Marijn Verhoef, Director of Operations and Research at the Access to Medicine Foundation examines the interconnected challenges of drug shortages and antimicrobial resistance. Verhoef urges decisive and urgent action from…
The EMA’s Peter Arlett looks back on two years of the Accelerating Clinical Trials in the European Union (ACT EU) initiative which aims to improve the environment for clinical trials…
New methodology for the 2024 Access to Medicine Index promises a stronger attempt to quantify whether drugs, vaccines, and diagnostics are actually making it all the way to patients in…
Claudia Martínez, generic & biosimilar medicines programme manager at the Access to Medicine Foundation, draws from a recent AMF report to outline what more generics companies can be doing to…
As part of a wide-ranging conversation with PharmaBoardroom published earlier this month, European Medicines Agency (EMA) Executive Director Emer Cooke laid out four of the Agency’s core focus areas for…
In conversation at DIA Europe 2023 in Basel, European Medicines Agency Executive Director Emer Cooke looks back at the lessons EMA has taken from the COVID-19 pandemic response, outlines the…
The Access to Medicine Index, a biennial report that gauges the efforts of the world’s largest pharma companies to expand access in low- and middle-income countries (LMICs), found in this…
The latest news from the Dutch pharma, biotech and healthcare industries, including the bullish comments of Argenx CEO Tim Van Hauwermeiren following the successful launch of its Vyvgart product; cancer…
The European Medicines Agency (EMA), the EU body responsible for the evaluation of medicinal products for use within the European Union, concluded a vote on Monday evening in Brussels following…
Leo de Haan of Aurobindo discusses how to maintain a profitable business in times of rock-bottom generics prices in the Netherlands, the resulting second pillar of specialty products for the…
Despite lacking a national champion to bolster its innovative eco-system since the 2007 acquisition of Organon by Schering Plough, the Netherlands nevertheless still sits in fourth position on the 2015…
See our Cookie Privacy Policy Here
